Last reviewed · How we verify

Gout Prevention — Treatment Landscape & Competitive Intelligence

Gout Prevention (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Gout Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Uloric FEBUXOSTAT Takeda Xanthine Oxidase Inhibitor [EPC] Xanthine dehydrogenase/oxidase 2009-01-01
Colcrys COLCHICINE Scilex Pharms Alkaloid [EPC] Serine/threonine-protein kinase pim-1 1961-01-01
Adenuric Adenuric Pharmtechnology LLC Flavin reductase (NADPH), ATP-binding cassette sub-family G member 2, Potassium voltage-gated channel subfamily H member 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pharmtechnology LLC · 1 drug in Gout Prevention
  2. Scilex Pharms · 1 drug in Gout Prevention
  3. Takeda · 1 drug in Gout Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Gout Prevention:

Cite this brief

Drug Landscape (2026). Gout Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/gout-prevention. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing